Hot Products

Dipsacussaponin PE
Catalog No: CFN90396

Reference standards.

Dipsanoside A
Catalog No: CFN90753

Dipsanoside A is a natural product from Dipsacus asperoides.

Dipsanoside B
Catalog No: CFN90754

Dipsanoside B is a natural product from Dipsacus asperoides.

Dipterocarpol
Catalog No: CFN98705

Dipterocarpol is a dammarane-type triterpenoid, as are the major bioactive compounds of ginseng. Dipterocarpol A shows moderate acetylcholinesterase inhibitory activity with the IC50 value of 8.28 uM.

Discodermide
Catalog No: CFN00114

Discodermide has antifungal and cytotoxic activities.

DL-alpha-Tocopherol
Catalog No: CFN90041

DL-alpha-tocopherol, a potent inhibitor of phorbol ester induced shape change of erythro- and megakaryoblastic leukemia cells. DL-alpha-tocopherol acetate protects endothelial cell membranes from oxidative damage and disruption and limits the magnitude of haemorrhage and its spread from the subependyma into the ventricles; it also protects human skin fibroblasts against the cytotoxic effect of UVB, and its mechanism seems to be related to inhibition of UV-induced lipid peroxidation or to the antioxidation effect of dl-alpha-tocopherol.

d-Laserpitin
Catalog No: CFN92710

Reference standards.

DL-Malic acid
Catalog No: CFN70170

DL-malic acid supplementation improves the carcass characteristics of finishing Pelibuey lambs. DL-malic acid can inhibit the floatability of muscovite.

DL-Menthol
Catalog No: CFN99160

DL-Menthol has short term toxicity in rats, it plays a role in the induction of surgical anesthesia in fishes, related at least in part to the activation of GABAA receptors, and of rapid movement possibly via cold nociceptors.

DL-Syringaresinol
Catalog No: CFN99276

(+)-Syringaresinol shows inhibitory activity of Helicobacter pylori motility with the IC50 value is 50 microg/ml. (-)-Syringaresinol has been reported to potently inhibit the proliferation of human promyelocytic HL-60 cells through G 1 arrest and induction of apoptosis, suggests that it may be a potential chemotherapeutic agent for the treatment of cancer. Syringaresinol induces vasorelaxation by enhancing NO production in endothelial cells via two distinct mechanisms, phosphatidylinositol 3-kinase/Akt- and (PLC)/Ca2+/CaMKKβ -dependent eNOS phosphorylation and Ca(2+)-dependent eNOS dimerization. Syringaresinol also can protect against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1α in a FOXO3-dependent mechanism.